Pfizer, along with its German partner BioNTech , and Moderna have together locked up over $60 billion in sales of the shots just in 2021 and 2022. The agreements include supply of the initial two doses of their vaccines as well as billions of dollars in potential boosters for wealthy nations.
The vaccine makers say that evidence of waning antibody levels in vaccinated people after six months, as well as an increasing rate of breakthrough infections in countries hit by the Delta variant, support the need for booster shots. As a result, it is far from clear how many people will need boosters, and how often. The profit potential of booster shots may be limited by the number of competitors who enter the market. In addition, some scientists question whether there is enough evidence that boosters are needed, particularly for younger, healthy people. The World Health Organization has asked governments to hold off on booster shots until more people worldwide receive their initial doses.
Pfizer declined to comment for the story. During the company’s second-quarter earnings call, executives said they believe a third dose will be necessary 6 to 8 months after vaccination, and regularly afterward.Abby Oplinger, 13, receives the Pfizer-BioNTech coronavirus disease vaccine after Pennsylvania authorized the vaccine for those over 12-years-old at Skippack Pharmacy in Schwenksville, Pennsylvania, U.S., May 12, 2021.
Pity politics killed off AstraZeneca's profit free vaccine. It's been spectacularly successful in the UK and is around $2 a shot compared to Pfizer at $16.
Only is societies allow them to 💁🏿♂️
They're going milk this cash cow until the nips fall off. They won't cure this one like polio. There isn't any money in that.